In a significant breakthrough for oncology, a long-term study has revealed that a personalized mRNA vaccine, when administered in tandem with standard immunotherapy, continues to provide a durable and potent defense against melanoma recurrence five years post-surgery. The findings, stemming from the phase 2b KEYNOTE-942 trial, offer renewed hope for patients facing the aggressive nature of skin cancer, demonstrating that combining innovative genetic technology with existing clinical standards can fundamentally alter patient outcomes.
The study, led by researchers at NYU Langone Health and its Perlmutter Cancer Center, provides robust evidence that the vaccine—known as intismeran—maintains its efficacy long after the initial treatment phase. With a 49% reduction in the risk of recurrence or death, the results mark a pivotal moment in the evolution of personalized medicine.
Main Facts: The Power of Combination Therapy
The core of the clinical trial involved 107 patients who had undergone surgical removal of their melanoma tumors. These participants were randomized to receive a combination of the personalized mRNA vaccine, intismeran, alongside the widely used immunotherapy drug pembrolizumab (Keytruda). Their outcomes were compared against a control group of 50 patients who received pembrolizumab alone—the current standard of care for high-risk melanoma.
After a rigorous five-year follow-up, the data presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago was striking. Approximately 68.8% of patients in the combination therapy group remained cancer-free, compared to just 49.1% in the group receiving immunotherapy alone.
Beyond simply preventing local recurrence, the vaccine demonstrated a profound ability to protect against systemic failure. The risk of distant metastasis—where cancer spreads to vital organs such as the lungs, liver, or brain—was reduced by 59% in the vaccine cohort. Perhaps most importantly, the overall survival rate reached 92.2% for those receiving the combination therapy, compared to 71.3% for those treated with pembrolizumab alone.
Chronology of the KEYNOTE-942 Trial
The journey toward these results began between 2019 and 2021, when the trial was officially enrolled at various cancer centers across the United States and Australia. The recruitment focused on patients who had already undergone surgery to remove their tumors, providing the researchers with the unique opportunity to analyze the genetic profile of each patient’s individual cancer.
- 2019–2021: Enrollment phase for 157 participants, with tumors surgically resected and analyzed for 34 patient-specific neoantigens.
- Post-Surgery: Patients were randomized; one group received standard pembrolizumab, while the other received the combination of pembrolizumab and the personalized intismeran vaccine.
- Ongoing Monitoring: Researchers tracked patient health, documenting side effects, recurrence rates, and metastasis over a five-year window.
- June 2026: Presentation of the final five-year results at the ASCO meeting and simultaneous publication in the Journal of Clinical Oncology.
- Present Day: Expansion into phase 3 multicenter trials to determine the efficacy of intismeran as a first-line treatment, with concurrent studies exploring its application in lung and other high-mutation cancers.
The Mechanism: How Intismeran Works
To understand the success of this trial, one must look at the biological interplay between T cells, cancer cells, and mRNA technology.
Harnessing the Immune System
T cells are the "soldiers" of the immune system, designed to identify and destroy foreign invaders. However, cancer cells are masters of disguise. They often exploit "checkpoint" molecules on the surface of T cells to signal that they are not a threat, essentially turning off the immune response. Pembrolizumab, a PD-1 inhibitor, blocks these checkpoint molecules, effectively "taking the blindfold off" the T cells so they can recognize and attack the cancer.
The Role of mRNA Neoantigens
While immunotherapy clears the path for the immune system, the vaccine provides the "wanted poster." By analyzing the tumors removed from patients, researchers identified up to 34 unique neoantigens—proteins specific to the individual’s cancer.
Intismeran, an mRNA vaccine, carries the genetic instructions for these neoantigens. Once injected, the vaccine instructs the body’s cells to produce these proteins, training the immune system to recognize them as distinct markers of cancer. This creates a highly specific, personalized army of T cells that are primed to hunt down any lingering or emerging melanoma cells expressing those specific markers.
Official Responses and Expert Insight
Dr. Janice Mehnert, the senior investigator of the study and a professor at the NYU Grossman School of Medicine, underscored the gravity of these findings. "Our study offers strong evidence to melanoma patients that intismeran vaccine therapy, when used in combination with immunotherapy, can demonstrably reduce their risk of having their cancer return and improve clinical outcomes," she stated.
Dr. Mehnert, who also serves as the director of the melanoma medical oncology program at Perlmutter Cancer Center, emphasized the broader implications for the medical community. "Our findings also serve as encouragement to cancer researchers globally that mRNA vaccines like intismeran could work well in combination with immunotherapy for other cancers whose high rates of mutations have proven difficult to target."
The medical community has reacted with cautious optimism, noting that while the side effects—which included manageable fatigue, chills, and injection site pain—were consistent with immunotherapy, the gain in long-term survival is unprecedented for this patient population.
Clinical and Global Implications
The success of the KEYNOTE-942 trial ripples far beyond the treatment of melanoma. As the most common form of skin cancer in the United States, with an estimated 112,000 new cases projected for 2026, melanoma has long been a primary target for oncological innovation.
A New Standard of Care?
The current results provide a strong argument for the integration of personalized mRNA vaccines into the standard postoperative protocol for melanoma. By shifting from a "one-size-fits-all" approach to a "bespoke" therapeutic strategy, clinicians may be able to significantly lower the rate of recurrence in high-risk patients.
Applicability to Other Cancers
The "high-mutation" nature of melanoma makes it an ideal candidate for this type of vaccination. However, researchers are already looking toward other difficult-to-treat cancers. The success of the trial has accelerated interest in using similar mRNA platforms for lung cancer and other solid tumors that possess enough genetic complexity to yield distinct neoantigens.
The Economic and Logistical Horizon
While the clinical results are promising, the logistical challenge of manufacturing personalized vaccines for every patient remains a hurdle. The collaboration between Moderna, the manufacturer of intismeran, and Merck & Co., the manufacturer of pembrolizumab, signals a concerted effort to scale these technologies. As the phase 3 multicenter trials continue, the focus will likely shift toward the efficiency of the manufacturing pipeline and ensuring that these life-saving treatments become accessible to a wider patient population.
Conclusion
The five-year follow-up of the KEYNOTE-942 trial confirms that we are entering a new era of cancer care. The combination of intismeran and pembrolizumab does not merely treat cancer; it educates the body to remain vigilant against it. As the medical community digests these results, the focus now turns to the upcoming phase 3 trials. If these results are replicated on a larger scale, the paradigm of cancer treatment will have shifted permanently from reactive systemic therapy to proactive, personalized immune defense, providing patients with not just more time, but a better quality of life in the years following their diagnosis.
About the Author
